About Freya Biosciences
Freya Biosciences is a Healthcare company based in Copenhagen (Denmark) founded in 2023 by Johan E T Van Hylckama Vlieg, Colleen Acosta, and Thomas Gundelund Rasmussen. Freya Biosciences is focused on developing microbial immunotherapies for womens reproductive health. It operates on a HealthTech model. Freya Biosciences has raised $49.8 million across 2 funding rounds from investors including Gates Foundation, Danmarks Eksport og Investeringsfond and Sofinnova Partners. The company has 16 employees. Its chief executive, as recorded, is Colleen Acosta. Freya Biosciences offers products and services including FB101, IVF Support Therapy, and Endometriosis Treatment. Its focus areas include Biotechnology and Women's Health.
Company details
Freya Biosciences is engaged in creating innovative microbial immunotherapies to address chronic inflammation and immune dysregulation in womens reproductive health. Solutions are developed for conditions such as infertility, endometriosis, and preterm birth. The company is supported by a data-driven platform integrating clinical trial results and extensive microbiome and immune marker data. Research and therapeutic development are targeted at improving outcomes in IVF, natural conception, and other reproductive system disorders. Partnerships, such as with Boston IVF, are established to advance clinical studies in the US.
- Headquarters Copenhagen, Denmark
- Employees 16
- Founders Johan E T Van Hylckama Vlieg, Colleen Acosta, Thomas Gundelund Rasmussen
- SectorsHealthcare
- Website freyabiosciences.com
- Social LinkedIn X Instagram
- Net Profit-$11.77 M (USD)-152as on Dec 31, 2023
- EBITDA-$12.57 M (USD)-121as on Dec 31, 2023
- Total Equity Funding$49.8M (USD)
in 2 rounds
- Latest Funding Round$11.8M (USD), Series A
Nov 2024
- InvestorsGates Foundation
& 7 more
- Employee Count16
Products & Services of Freya Biosciences
Freya Biosciences offers a comprehensive portfolio of products and services, including FB101, IVF Support Therapy, and Endometriosis Treatment.
Therapeutic solution targeting vaginal dysbiosis for women.
Therapy addressing dysbiosis for improved IVF outcomes.
Treatment targeting dysbiosis linked to endometriosis infertility.
Funding Insights of Freya Biosciences
Freya Biosciences has successfully raised a total of $49.8M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.8 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.8M
- Total Rounds 2
- Last Round Series A — $11.8M
- First Round $38M
(Dec 2023)
- Investors Count 8
All 2 funding rounds of Freya Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $11.8M | Series A | – | Gates Foundation, Danmarks Eksport og Investeringsfond | – |
| Dec 2023 | $38M | Series A | – | Sofinnova Partners, OMX Ventures |
8 investors in total: 8 institutional.
Investors in Freya Biosciences
Freya Biosciences has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Danmarks Eksport og Investeringsfond and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Venture capital investments are made in transformative biotech companies by OMX Ventures. | omx.vc | Lincolnshire, USA | ||
Angelini Ventures is focused on investing in BioTech and Digital Health. | angeliniventures.com | Rome, Italy | ||
Venture capital investments are managed by Indaco in Italy. | 2016 | indacosgr.com | Milan, Italy | |
| csb.co.jp | ||||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Financial services are provided for export and investment sectors. | 2022 | eifo.dk | Hellerup, Denmark | |
Services across port management, logistics, aviation and procurement and construction industry | crescententerprises.com | Sharjah, United Arab Emirates |
Investor details for Freya Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Freya Biosciences
3 people are tracked at Freya Biosciences (3 in leadership); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Johan E T Van Hylckama Vlieg | Co-Founder & CSO | Leadership |
Colleen Acosta | Co-Founder & CEO | Leadership |
Thomas Gundelund Rasmussen | Co-Founder | Leadership |
Complete people profiles for Freya Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Freya Biosciences
3 dated milestones of Freya Biosciences across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Freya Biosciences is founded.
- Funding First funding round of $38.0M.
- Funding Latest funding round, Series A, of $11.8M.
Web traffic of Freya Biosciences
The website of Freya Biosciences (freyabiosciences.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 11.4% vs previous month
Websites whose visitors overlap most with Freya Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gehealthcare.dk | gehealthcare.dk | 100% | #4,499,970 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Freya Biosciences
Complete news archive for Freya Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Freya Biosciences
Freya Biosciences was founded in 2023.
Freya Biosciences is headquartered in Copenhagen, Denmark.
Colleen Acosta is the CEO of Freya Biosciences, as recorded in our data. They have also founded this company.
Freya Biosciences is a funded company, having raised a total of $49.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $38M, raised on Dec 2023.
Freya Biosciences has 16 employees.
Freya Biosciences is engaged in creating innovative microbial immunotherapies to address chronic inflammation and immune dysregulation in womens reproductive health. Solutions are developed for conditions such as infertility, endometriosis, and preterm birth. The company is supported by a data-driven platform integrating clinical trial results and extensive microbiome and immune marker data. Research and therapeutic development are targeted at improving outcomes in IVF, natural conception, and other reproductive system disorders. Partnerships, such as with Boston IVF, are established to advance clinical studies in the US.
Freya Biosciences offers FB101, IVF Support Therapy, and Endometriosis Treatment.
Freya Biosciences has 8 investors. Key investors include Gates Foundation, Danmarks Eksport og Investeringsfond, Sofinnova Partners, OMX Ventures, and Angelini Ventures.